BrainChild Bio closes $116m Series A to fund pivotal DIPG CAR-T trial
BrainChild Bio has closed a $116 million Series A financing round to advance its CAR T cell therapy pipeline targeting central nervous system tumours, with the bulk of the capital earmarked for a pivotal clinical trial in one of the most intractable paediatric cancers.
The round was led by an undisclosed private family fund and foundation, with participation from Seattle Children's, which had been the company's sole initial backer, and new investor WRF Capital. BrainChild Bio did not disclose a post-money valuation.
The ILLUMINATE trial and BCB-276
Primary use of proceeds is the ILLUMINATE Phase 2 study (NCT07680439), a registrational trial evaluating BCB-276, the company's autologous B7-H3-targeted CAR T cell therapy, in diffuse intrinsic pontine glioma (DIPG). DIPG is a high-grade paediatric brainstem tumour that is uniformly fatal; approximately 300 children are diagnosed annually in the United States, predominantly between the ages of five and ten. Median overall survival on current standard-of-care palliative radiotherapy is roughly eleven months from diagnosis.
BCB-276 is engineered for locoregional delivery directly into the cerebrospinal fluid via an in-dwelling reservoir-catheter, a route the company says allows repeated dosing at the tumour site while limiting systemic toxicity. The study is designed to support a future Biologics Licence Application with the US Food and Drug Administration. A second programme, BCB-214, is a triple-targeting CAR T cell therapy being readied for initial clinical testing in glioblastoma, and Series A funds will also support its early development.
"We believe the time is right to show the breakthrough potential for our CAR T cell therapeutic approach with BCB-276 for DIPG," said Steven Brugger, chief executive of BrainChild Bio, referencing a disease he described as devastating for children and their families. Michael Jensen, founder and chief scientific officer, said the financing "represents a new paradigm for treating CNS brain tumours in children and adults."
Market context and competitive landscape
CAR T cell therapy for solid tumours, and CNS tumours in particular, remains a frontier challenge that has frustrated much of the broader cell therapy industry. Approved commercial CAR-T products from Novartis, Bristol Myers Squibb and Kite Pharma address haematological malignancies, where CAR T cells can traffic freely through the bloodstream; replicating that efficacy in solid tumours infiltrated behind the blood-brain barrier is a substantially harder problem.
BrainChild Bio's locoregional delivery strategy is one of several approaches under active investigation. A number of academic centres and clinical-stage companies are pursuing intratumoral or intrathecal CAR T cell infusion for glioblastoma and DIPG, and early clinical signals from some of those programmes have generated interest in the field. The company's technology is licensed exclusively from Seattle Children's, where much of the foundational clinical experience was developed, giving it a distinct starting point that includes prior-generation dosing and safety data.
The Series A structure is notable: an undisclosed family fund and foundation taking a lead position is uncommon at this scale and may reflect the mission-driven, paediatric framing of the programme rather than purely commercial return expectations. Investors considering BrainChild Bio's longer-term trajectory will be watching ILLUMINATE enrolment rates, interim safety readouts, and whether the company moves to broaden its investor base ahead of a potential Series B to fund the glioblastoma programme in adults.